B · Normal
[Yuekang Pharmaceutical: Subsidiary YKYY018 atomized inhalation has been approved for clinical trials by the FDA] On November 12, Yuekang Pharmaceutical (688658.SH) announced that the company's subsidiary Yuekang Kechuang has recently received FDA approval for clinical trials of YKYY018 atomized inhalation for the treatment and prevention of human parainfluenza virus infection. This product is a membrane fusion inhibitor drug independently developed by the company. It has previously been approved by the FDA and NMPA to conduct clinical trials for RSV and hMPV infections. Preclinical studies have shown that this product has significant inhibitory effects on a variety of respiratory viruses and has good safety profile.
A-share announcement express 🕐 2026-11-12 17:20
#clinical trial #Virus #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[SMIC: Net profit in the third quarter increased by 87.6% year-on-year] On Novem 11-12 17:36 [Sobao Protein: Chairman proposes to repurchase 20 million to 40 million yuan of 11-12 17:24 [Nanwei Medical: Chairman proposes to repurchase 20 million to 30 million yuan o 11-12 17:21 [Tuojing Technology: The matter of issuing shares to purchase assets and raising 11-12 16:48 [Junda Shares: Termination of Oman’s 5GW high-efficiency battery project] On Nov 11-12 16:45 [Hengrui Pharmaceuticals: Subsidiary’s Class 1 new drug rifucibamab injection ha 11-12 16:43

Comments

0/500
Captcha (click to refresh)
No comments yet